Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Interest & Investment Income came in at $1.2 million in Q1 2026, up 2.3% YoY from $1.2 million in Q1 2025, and up 3.8% on a QoQ basis from $1.2 million in Q3 2025.
Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Interest & Investment Income data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Interest & Investment Income rose 2.3% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 63.73% YoY) and the FY2024 annual result came in at $5.3 million, up 266150.0% from the prior year.
- Interest & Investment Income improved to $1.2 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $5.3 million in Q4 2024 to a low of -$3.6 million in Q4 2023.
- A 5-year average of $566733.3 and a median of $68000.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income tumbled 30483.33% — and 2024, when it surged 32150.0%.
- Tracing XERS's Interest & Investment Income over 5 years: stood at $12000.0 in 2022, then plunged by 30483.33% to -$3.6 million in 2023, then surged by 245.69% to $5.3 million in 2024, then sank by 78.2% to $1.2 million in 2025, then increased by 3.8% to $1.2 million in 2026.
- The last three Interest & Investment Income figures came in at $1.2 million (Q1 2026), $1.2 million (Q3 2025), and $1.2 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.46 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 1.92 Mn |
| Dec 31, 2023 | -3.65 Mn |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | -49,000.00 |
| Mar 31, 2023 | -6,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Mar 31, 2022 | 68,000.00 |
| Dec 31, 2021 | -281,000.00 |
| Sep 30, 2021 | 66,000.00 |
| Jun 30, 2021 | 77,000.00 |
| Mar 31, 2021 | 100,000.00 |